This site is intended for healthcare professionals
Drug news

NICE does not recommend Besponsa (inotuzumab ozogamicin) to treat relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia.- Pfizer

Read time: 1 mins
Last updated:29th Aug 2017
Published:23rd Aug 2017
Source: Pharmawand
Register for free access to this exclusive healthcare learning resource


Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest